ArticleObesity science & practice2026
Patient Knowledge of GLP-1 Receptor Agonists for Obesity and Exploration of Potential Household-Level Effects in an Urban Health System.
Article in Obesity science & practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity management has gained widespread popularity and media attention. However, little is known about patients' knowledge related to GLP-1 RAs (e.g., prescribing indications, side effects), how patients currently learn and wish to learn about GLP-1 RAs, and how GLP-1 RA use may impact weight-related behaviors and attitudes within households (e.g., food purchasing patterns). Objective: This study evaluated these questions among diverse adults recruited from a large, urban health system. Methods: Participants were recruited to complete a brief online questionnaire through flyers posted in several outpatient clinics within a large health system. Recruitment occurred from November 2024 to April 2025. Descriptive statistics were calculated. Results: Fifty-two patients completed the questionnaire. Overall, 98% of participants had heard at least "a little" about GLP-1 RAs. The conditions participants most commonly believed could benefit from use were obesity (88%), diabetes (75%), and high blood pressure (43%). The side effects they had heard most about were nausea/vomiting (71%), diarrhea (49%), and constipation (47%). Expected amount of weight loss and understanding of GLP-1 RAs' mechanisms of action varied widely. The most common GLP-1 RA information source was commercials/advertisements (73%); however, the most frequently preferred information source was healthcare professionals (87%). In exploratory analyses among patients with current or past GLP-1 RA use and ≥ 1 other household member ( Conclusion: These findings suggest that many patients understand the primary indications for GLP-1 RAs for obesity and common side effects, while also highlighting opportunities for improved decision support. Additional research on a potential "ripple effect" within households using larger samples and more robust methods is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.